Earnings Report Overview#
Boston Scientific Corporation, based in Marlborough, Massachusetts, recently released its first quarter earnings report. While the company exceeded quarterly earnings expectations, its full-year profit outlook did not meet Wall Street's forecasts, leading to a decline in its stock price.
Quarterly Performance#
In the first quarter, Boston Scientific reported adjusted earnings per share (EPS) of $0.80, slightly above the analyst consensus of $0.79. The company generated revenue of $5.20 billion, which was just above the expected $5.17 billion and marked an 11.6% increase from $4.66 billion in the same quarter last year. On an organic basis, which excludes the effects of acquisitions and currency fluctuations, revenue grew by 9.4%.
Disappointing Full-Year Guidance#
Despite the strong quarterly performance, Boston Scientific's full-year adjusted EPS guidance of $3.34 to $3.41 disappointed investors, as the midpoint of $3.38 is below the analyst consensus of $3.45. The company anticipates revenue growth of 7.0% to 8.5% on a reported basis and 6.5% to 8.0% on an organic basis for the full year.
Segment Growth and Future Expectations#
The Cardiovascular segment was a key driver of growth, reporting revenue of $3.50 billion, a 13.5% increase on a reported basis and 11.2% organically. The MedSurg segment also performed well, generating $1.70 billion, up 7.8% on a reported basis and 5.7% organically. For the second quarter, Boston Scientific expects revenue growth of 5.5% to 7.5% and adjusted EPS between $0.82 and $0.84. The company also announced positive results from clinical trials for its WATCHMAN FLX device and EKOS Endovascular System, which were presented at a recent medical conference.